ProQR Therapeutics (PRQR) Net Cash Flow (2013 - 2026)

ProQR Therapeutics has reported Net Cash Flow for 14 years, with the latest figure at -$14.0 million in Q1 2026.

• Quarterly Net Cash Flow rose 22.33% year-over-year to -$14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.9 million (down 234.11% YoY) and the FY2025 annual result came in at -$66.9 million, down 330.63% from the prior year.
• Net Cash Flow rose to -$14.0 million in Q1 2026 per PRQR's latest filing, from -$18.9 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $60.5 million in Q4 2024 and troughed at -$59.9 million in Q3 2022.
• A 5-year average of -$7.7 million and a median of -$14.0 million in 2026 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow sank 431.09% in 2022, then jumped 16634.98% in 2024.
• Over 5 years, Net Cash Flow stood at -$4.1 million in 2022, then soared by 108.75% to $361515.8 in 2023, then surged by 16634.98% to $60.5 million in 2024, then tumbled by 131.32% to -$18.9 million in 2025, then grew by 26.27% to -$14.0 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$14.0 million, -$18.9 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.